Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Tebentafusp in Primary Uveal Melanoma
NCT06414590Phase 2Recruiting
- Sponsor
- Thomas Jefferson University
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Bispecific Antibodies, TCR-Engineered T Cells, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tebentafusp in Uveal melanoma (UM), sponsored by Thomas Jefferson University. Primary endpoint: Regression of primary uveal melanoma. Started Sep 2025; status: recruiting.
02
Drugs
tebentafusp
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT06414590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06414590.